Trial Profile
Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab and Nivolumab plus Ipilimumab in Subjects with Virus-Positive and Virus-Negative Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 15 Nov 2023
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Anal cancer; Carcinoma; Cervical cancer; Gastric cancer; Head and neck cancer; Merkel cell carcinoma; Nasopharyngeal cancer; Oesophageal cancer; Penile cancer; Solid tumours; Squamous cell cancer; Vulvovaginal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CheckMate-358
- Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
- 21 Oct 2023 This trail has been completed in Spain according to European Clinical Trials Database record.
- 06 Jun 2023 Results (n=68) assessing the efficacy and safety of nivolumab with or without ipilimumab in patients with recurrent/metastatic Merkel cell carcinoma, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 12 Dec 2022 Status changed from active, no longer recruiting to completed.